3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
MedMen Enterprises's 3-Year ROIIC % for the quarter that ended in Jun. 2022 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for MedMen Enterprises's 3-Year ROIIC % or its related term are showing as below:
MMNFQ's 3-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.74 * Ranked among companies with meaningful 3-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
MedMen Enterprises 3-Year ROIIC % Related Terms
MedMen Enterprises 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for MedMen Enterprises's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MMNFQ vs ZTS, VTRS, NBIX: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MedMen Enterprises's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedMen Enterprises 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MedMen Enterprises's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where MedMen Enterprises's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
MedMen Enterprises (MMNFQ) has a 3-Year ROIIC % of 0.00 as of Jun. 2022. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MedMen Enterprises and its competitors.
Is MedMen Enterprises' 3-Year ROIIC % too high?
MedMen Enterprises' current 3-Year ROIIC % is 0.00.
How does MedMen Enterprises' 3-Year ROIIC % compare to ZTS and VTRS?
MedMen Enterprises' 3-Year ROIIC % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year ROIIC % is 3.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on MedMen Enterprises and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedMen Enterprises's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMen Enterprises stock overvalued right now?
MedMen Enterprises (MMNFQ) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For MedMen Enterprises (MMNFQ), the current 3-Year ROIIC % is 0.00 as of Jun. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MedMen Enterprises Inc is a American cannabis company dedicated to improving life with Cannabis for All. With operations across the United States in California, Nevada, Illinois, Arizona, Massachusetts, and New York, the company has MedMen and LuxLyte brands offering cannabis in consumer-preferred product forms for medical and recreational use. It produces and curates the consumer product assortment for retail operations in its local communities, and drives consumer loyalty with service and engaging in-store experience, combined with reward, delivery, and e-commerce programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MMNFQ has been successfully added to your 